XML 101 R84.htm IDEA: XBRL DOCUMENT v3.3.1.900
Selected Quarterly Financial Data (Unaudited) (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Revenues:                      
Product revenues $ 7,039 $ 9,133 $ 8,307 $ 8,821 $ 9,353 $ 11,623 $ 9,022 $ 7,348 $ 33,300 $ 37,346 $ 19,962
Research and development programs 3,348 2,266 3,433 3,784 5,149 5,936 6,917 5,043 12,831 23,045 19,788
Total revenues 10,387 11,399 11,740 12,605 14,502 17,559 15,939 12,391 46,131 60,391 39,750
Costs and operating expenses:                      
Cost of product revenue 4,578 4,570 4,361 4,670 6,154 6,598 4,470 3,390 18,179 20,612 6,385
Research and development 9,586 13,207 12,747 12,554 18,210 20,571 22,064 20,835 48,094 81,680 66,572
Sales, general and administrative 18,888 19,596 20,981 21,268 22,139 25,883 21,637 20,607 80,733 90,266 62,933
Restructuring charges 4,581 (21) (31) 424 3,514 0 0 0 4,953 3,514 0
Total costs and operating expenses 37,633 37,352 38,058 38,916 50,017 53,052 48,171 44,832 151,959 196,072 135,890
Loss from operations (27,246) (25,953) (26,318) (26,311) (35,515) (35,493) (32,232) (32,441) (105,828) (135,681) (96,140)
Other income (expense):                      
Interest and other income, net (3,323) (3,225) (3,410) (3,273) (3,205) (3,188) (4,662) (1,112)      
Loss from equity method investments (4,098) (5,916) (7,309) (5,066) (7,724) (7,201) (4,278) (3,834) (22,389) (23,037) (8,237)
Gain from change in fair value of warrant liability 0 0 0 0 0 0 0 688 0 688 147
Gain (loss) from change in fair value of derivative liability (26) 176 (134) (15) 1,578 6,205 (1,745) 2,018 1 8,056 (6,392)
Total other expense, net (7,447) (8,965) (10,853) (8,354) (9,351) (4,184) (10,685) (2,240) (35,619) (26,460) (20,249)
Net loss $ (34,693) $ (34,918) $ (37,171) $ (34,665) $ (44,866) $ (39,677) $ (42,917) $ (34,681) $ (141,447) $ (162,141) $ (116,389)
Net loss per share attributable to Solazyme, Inc. common stockholders:                      
Basic and diluted (in dollars per share) $ (0.43) $ (0.43) $ (0.46) $ (0.44) $ (0.57) $ (0.50) $ (0.56) $ (0.50) $ (1.76) $ (2.14) $ (1.81)
Weighted-average number of shares used in loss per share computation:                      
Basic and diluted (in shares) 80,600,000 80,298,000 80,098,000 79,650,000 79,330,000 78,867,000 75,963,000 69,213,000 80,165,402 75,879,208 64,211,958